Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2007 1
2008 4
2009 5
2010 2
2011 6
2012 11
2013 14
2014 11
2015 11
2016 17
2017 11
2018 11
2019 9
2020 5
2021 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 26731175

101 results

Results by year

Filters applied: . Clear all
Page 1
Tenofovir/emtricitabine metabolites and endogenous nucleotide exposures are associated with p16(INK4a) expression in subjects on combination therapy.
Dumond JB, Francis O, Cottrell M, Trezza C, Prince HM, Mollan K, Sykes C, Torrice C, White N, Malone S, Wang R, Van Dam C, Patterson KB, Hudgens MG, Sharpless NE, Forrest A. Dumond JB, et al. Antivir Ther. 2016;21(5):441-5. doi: 10.3851/IMP3017. Epub 2016 Jan 5. Antivir Ther. 2016. PMID: 26731175 Free PMC article.
Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV-Infected Subjects With Aging Biomarkers.
Dumond JB, Chen J, Cottrell M, Trezza CR, Prince H, Sykes C, Torrice C, White N, Malone S, Wang R, Patterson KB, Sharpless NE, Forrest A. Dumond JB, et al. CPT Pharmacometrics Syst Pharmacol. 2017 Feb;6(2):128-135. doi: 10.1002/psp4.12151. Epub 2016 Dec 29. CPT Pharmacometrics Syst Pharmacol. 2017. PMID: 28032946 Free PMC article. Clinical Trial.
p16INK4a , a Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV-Infected Subjects.
Dumond JB, Collins JW, Cottrell ML, Trezza CR, Prince H, Sykes C, Torrice C, White N, Malone S, Wang R, Patterson KB, Sharpless NE, Forrest A. Dumond JB, et al. CPT Pharmacometrics Syst Pharmacol. 2017 Feb;6(2):120-127. doi: 10.1002/psp4.12150. Epub 2016 Dec 26. CPT Pharmacometrics Syst Pharmacol. 2017. PMID: 28019088 Free PMC article. Clinical Trial.
Concentrations of Pro-Inflammatory Cytokines Are Not Associated with Senescence Marker p16INK4a or Predictive of Intracellular Emtricitabine/Tenofovir Metabolite and Endogenous Nucleotide Exposures in Adults with HIV Infection.
Maas BM, Francis O, Mollan KR, Lee C, Cottrell ML, Prince HM, Sykes C, Trezza C, Torrice C, White N, Malone S, Hudgens MG, Sharpless NE, Dumond JB. Maas BM, et al. PLoS One. 2016 Dec 30;11(12):e0168709. doi: 10.1371/journal.pone.0168709. eCollection 2016. PLoS One. 2016. PMID: 28036343 Free PMC article. Clinical Trial.
Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.
McComsey GA, Daar ES, O'Riordan M, Collier AC, Kosmiski L, Santana JL, Fichtenbaum CJ, Fink H, Sax PE, Libutti DE, Gerschenson M. McComsey GA, et al. J Infect Dis. 2013 Feb 15;207(4):604-11. doi: 10.1093/infdis/jis720. Epub 2012 Nov 29. J Infect Dis. 2013. PMID: 23204164 Free PMC article. Clinical Trial.
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.
McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, Myers L, Melbourne K, Ha B, Sax PE. McComsey GA, et al. J Infect Dis. 2011 Jun 15;203(12):1791-801. doi: 10.1093/infdis/jir188. J Infect Dis. 2011. PMID: 21606537 Free PMC article. Clinical Trial.
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Yale K, Szwarcberg J, White K, Cheng AK, Kearney BP; GS-236-0103 Study Team. DeJesus E, et al. Lancet. 2012 Jun 30;379(9835):2429-2438. doi: 10.1016/S0140-6736(12)60918-0. Lancet. 2012. PMID: 22748590 Clinical Trial.
101 results